Product
VK2735
2 clinical trials
2 indications
Indication
Unintentional Weight LossIndication
NASHClinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid ConditionStatus: Active (not recruiting), Estimated PCD: 2024-02-27
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735, a Dual Glucagon-like Peptide-1 and Gastric Inhibitory Polypeptide Receptor Agonist, in Healthy Adults and Otherwise Healthy Adults Who Have an Increased Body Mass IndexStatus: Recruiting, Estimated PCD: 2023-11-01